Update
$Dare Bioscience(DARE.US$ Daré Bioscience Announces Publication Of Phase 2b Study Efficacy Results Of Topical Sildenafil Cream, 3.6% For The Treatment Of Female Sexual Arousal Disorder In Obstetrics & Gynecology
Benzinga
Phase 2b study demonstrated topical Sildenafil Cream, 3.6% improved outcomes among women with female sexual arousal disorder (FSAD), particularly in an exploratory subset of women with FSAD with or without concomitant decreased desire
There are currently no FDA-approved therapies for FSAD
Benzinga
Phase 2b study demonstrated topical Sildenafil Cream, 3.6% improved outcomes among women with female sexual arousal disorder (FSAD), particularly in an exploratory subset of women with FSAD with or without concomitant decreased desire
There are currently no FDA-approved therapies for FSAD
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
